Mucin-rich and mucin-poor colorectal signet ring cell carcinoma: clinicopathological characteristics and prognostic significance
This study demonstrates that colorectal signet ring cell carcinoma can be stratified into mucin-rich and mucin-poor subtypes, with the latter exhibiting more aggressive clinicopathological features, a higher prevalence of BRAF V600E mutations, and significantly worse survival outcomes, thereby supporting the inclusion of mucin phenotyping in standard pathological evaluation to guide treatment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is not a single disease but a collection of many different conditions that happen to share a name. Within the large family of colorectal cancer, which affects the colon and rectum, doctors have long recognized that some tumors look and behave differently under a microscope. One particularly aggressive type is known as signet ring cell carcinoma. These tumors get their name from the way their cells appear: the inside of the cell is filled with a sticky, gel-like substance called mucin that pushes the nucleus to the side, giving the cell a shape that resembles a signet ring. For decades, medical professionals treated all signet ring cell carcinomas as a single, uniform group, assuming they all shared the same dangerous nature and responded to treatment in the same way. However, this assumption has begun to crumble as researchers realized that these tumors might actually be two very different things wearing the same mask.
A new study from researchers at the Sixth Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, sets out to test this idea by looking closely at the amount of that sticky mucin present in the tumor. The team examined 119 patients who had undergone successful surgery to remove their colorectal signet ring cell tumors between 2010 and 2023. They carefully sorted these cases into two groups based on what they saw in the tissue samples: those with a lot of extracellular mucin, which they called "mucin-rich," and those with very little, which they called "mucin-poor." The goal was to see if this simple visual difference could predict how the disease would behave and how the patients would fare over time.
The results of this investigation reveal a stark divide between the two groups. The patients with the mucin-poor tumors faced a much more difficult battle. These tumors were found to be significantly more aggressive, showing a higher tendency to invade nerves and blood vessels, and they were more likely to leave behind small clusters of cancer cells in the surrounding tissue. In contrast, the mucin-rich tumors, while still serious, behaved in a slightly less chaotic manner. The researchers also looked at the genetic makeup of these tumors and found a crucial difference: the mucin-poor group had a much higher rate of a specific genetic change known as a BRAF mutation. This mutation is known to drive rapid cell growth and spread, which helps explain why these tumors were so dangerous.
When the researchers followed the patients over time, the difference in outcomes was clear and severe. Patients with the mucin-poor tumors had significantly lower survival rates and were more likely to see their cancer return after surgery compared to those with the mucin-rich tumors. The data showed that the type of mucin present was not just a minor detail but a powerful predictor of the patient's future health, standing out as an independent factor that could determine the course of the disease. The study suggests that the old way of treating all signet ring cell carcinomas as the same is no longer accurate. Instead, doctors may need to look at the specific mucin profile of a tumor to understand its true nature. By identifying the mucin-poor subtype, which is linked to worse outcomes and specific genetic mutations, medical teams could potentially tailor more aggressive or targeted treatments for those patients, while offering a different approach for those with the mucin-rich variant. This work does not claim to have solved the problem of colorectal cancer, but it does provide a clearer map for navigating one of its most difficult forms, urging pathologists to include this distinction in their standard reports to help guide better care.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.